The information in this section is intended for visitors outside the United States.
More than 400 million people worldwide are living with chronic hepatitis B or C infection, making viral hepatitis many times more common than HIV. Chronic infection with the hepatitis B or C viruses can lead to serious and life-threatening liver damage, including liver cirrhosis (scarring), liver cancer and the need for liver transplantation.
Gilead has developed today’s leading medicines for viral hepatitis.
Gilead is working with regional partners to introduce branded Sovaldi® and Harvoni® in low- and middle-income countries, prioritizing those with the greatest disease burden. The company also works with 11 generic drug manufacturers in India to produce high-quality, low-cost generic versions of its chronic hepatitis C medicines for use in 101 developing countries.
Viread® (tenofovir disoproxil fumarate) is indicated for the treatment of chronic hepatitis B. We work with regional business partners and generic licensing partners to sell Viread for HBV at discounted prices in 130 developing countries. We are working to increase the number of access countries in which Viread is registered for HBV.